The company completed a new brand upgrade and officially changed its name to GeneMind Biosciences Company
GenoCare 1600 Single Molecular Sequencer successfully passed the medical device registration test.
The company moved to a new site and entered the Shenye Jinyuan Building in Luohu District. The total work area reached 8,000 square meters.
GenoCar 27 # became the company's first single-molecule sequencer product to enter the hospital for external testing.
The instrument production line of the sequencer with an area of more than 1,000 square meters was officially put into trial operation.
Get a total of 218 million yuan of A round of financing, which was jointly participated by five institutions, focused on the construction of the third-generation genetic sequencer and supporting reagent production lines and the declaration of medical device licenses.
The GMP standard kit production line with an area of more than 2,000 square meters was officially completed, and reagents and chips began to start trial production.
Completed the “non-invasive prenatal testing research based on the third-generation gene sequencer”, which is the first case in China to use the single-molecule sequencing technology for clinical detection of NIPT.
A successful prototype of GenoCare monolecular sequencer.
For the first time, single-molecule sequencing of biological samples and the release of sequencing data.
The results of single-molecule target sequencing based on the GenoCar principle prototype were officially published in the international academic journal Scientific Reports.
The prototype of the company's first single-molecule sequencer project, GenoCar alpha, was successfully developed.
Nature Biotechnology Journal Reports on GenoCare System.
First realization of single-molecule sequencer principle machine fully automated sequencing.
First achieving single-molecular image capture.
Direct Genomics was founded at Shenzhen， China.